# PepGen Stock More Than Doubles After Positive Midphase Data for Myotonic Dystrophy Type 1

PepGen’s share price more than doubled after the company released positive results from a Phase 2 trial of its experimental therapy for myotonic dystrophy type 1 (DM1). The data met what analysts described as a best-case scenario, according to a report from Fierce Biotech.

The midphase trial evaluated PepGen’s candidate in patients with DM1, a rare genetic disorder that causes progressive muscle weakness and other symptoms. Analysts had modeled a range of possible outcomes, and the actual results landed at the top end of expectations. The stock surge reflects investor enthusiasm for the clinical data, though the company has not yet disclosed specific numerical results.

PepGen’s approach uses a peptide-conjugated antisense oligonucleotide designed to target the underlying genetic cause of DM1. The Phase 2 readout is a key milestone for the company as it considers next steps toward a potential pivotal trial.

**Why this matters for life sciences**

Myotonic dystrophy type 1 is the most common form of muscular dystrophy in adults, affecting an estimated 1 in 8,000 people worldwide. No disease-modifying therapies are currently approved for DM1. Positive midphase data from PepGen’s trial could pave the way for the first treatment that addresses the root cause of the disease. The stock movement also illustrates how midphase clinical readouts can dramatically affect valuations for small-cap biotech companies, especially in areas of high unmet medical need.

Source: [original report](https://www.fiercebiotech.com/biotech/